Prostate Carcinoma: this chapter outlines the incidence, risk factors, clinical presentation, investigations, treatments and prognosis of cancer at this anatomical site. These features are correlated with the core data that are required to make corresponding histopathology reports of a consistently high quality, available in an appropriate timeframe, and clinically relevant to patient management and prognosis. Summary details of the common cancers given at this site include: gross description, histological types, tumour grade/differentiation, extent of local tumour spread, lymphovascular invasion, lymph node involvement, and the status of excision margins. Current WHO Classifications of Malignant Tumours and TNM8 are referenced. Notes are provided on other associated pathology, contemporary use of immunohistochemistry, updates on the role of evolving molecular tests, and the use of these ancillary techniques as biomarkers in diagnosis, and prediction of prognosis and treatment response. A summary is given of the more common non-carcinoma malignancies that are encountered at this site in diagnostic practice.
KeywordsProstatic adenocarcinoma TNM8 Gleason grade groups Immunohistochemistry Extraprostatic extension
- Epstein JI, Amin MB, Reuter VE, Humphrey PA. Contemporary gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol. 2017a;41:e1–7.CrossRefGoogle Scholar
- Epstein JI, Amin MB, Reuter VE. Contemporary gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2017b;41:e1–7.CrossRefGoogle Scholar
- Gleason D. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology. The prostate. Philadelphia, PA: Lea and Febiger; 1977. p. 171–98.Google Scholar
- Kench JG, Delahunt B, Griffiths DF, Humphrey PA, McGowan T, Trpkov K, Varma M, Wheeler TM, Srigley JR. Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the International collaboration on cancer reporting. Histopathology. 2013;62:203–18.CrossRefGoogle Scholar
- Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO classification of tumors of the urinary system and male genital organs. 4th ed. Lyon: IARC; 2016.Google Scholar
- Prendeville S, Gertner M, Maganti M. Role of magnetic resonance imaging targeted biopsy in detection of prostate cancer harboring adverse pathological features of intraductal carcinoma and invasive cribriform carcinoma. J Urol. 2018;S0022–5347:30175–7.Google Scholar
- The Royal College of Pathologists. Standards and datasets for reporting cancers Dataset for histopathology reports for prostatic carcinoma. 2016. https://www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html.
- Van der Kwast Th H, Lopes C, Santonja C, Pihl C-G, Neetens I, Martikainen P, Di Lollo S, Bubendolf L, Hoedemaeker RF, Members of the Pathology Committee of the European Randomised Study of Screening for Prostate Cancer (ERSPC). Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol. 2003;56:336–40.CrossRefGoogle Scholar